Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

Via MarketMinute

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Via MarketMinute

Topics Economy

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

Via The Motley Fool

Topics Intellectual Property

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

September 20, 2025

Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs ↗

September 20, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

Via The Motley Fool

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Via MarketMinute

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds ↗

September 19, 2025

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.

Via Benzinga

The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors. ↗

September 19, 2025

Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting.

Via Investor's Business Daily

Why Shares in Novo Nordisk Soared This Week ↗

September 19, 2025

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.

Via The Motley Fool

Why Novo Nordisk Stock Popped Again Today ↗

September 18, 2025

A Wegovy pill may be the right medicine to get Novo Nordisk stock moving again.

Via The Motley Fool

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today ↗

September 18, 2025

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.

Via The Motley Fool

Topics Government

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal ↗

September 18, 2025

Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's...

Via Benzinga

Topics Artificial Intelligence

Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy ↗

September 18, 2025

Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.

Via Investor's Business Daily

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study ↗

September 18, 2025

Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

September 18, 2025

Competition in various directions is affecting the company's fastest-growing product.

Via The Motley Fool

'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work ↗

September 18, 2025

Via Benzinga

Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch ↗

September 18, 2025

Via Stocktwits

Topics Economy Stocks

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗

September 17, 2025

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

Via Stocktwits

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

Headline News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today